Quantitative analysis of glycation sites on human serum albumin using (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
BACKGROUND
One of the long term complications of diabetes is the non-enzymatic addition of glucose to proteins in blood, such as human serum albumin (HSA), which leads to the formation of an Amadori product and advanced glycation end products (AGEs). This study uses (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to provide quantitative data on the extent of modification that occurs in the presence of glucose at various regions in the structure of minimally glycated HSA.


METHODS
Normal HSA, with no significant levels of glycation, was digested by various proteolytic enzymes in the presence of water, while a similar sample containing in vitro glycated HSA was digested in (18)O-enriched water. These samples were then mixed and the (16)O/(18)O ratios were measured for peptides in each digest. The values obtained for the (16)O/(18)O ratios of the detected peptides for the mixed sample were used to determine the degree of modification that occurred in various regions of glycated HSA.


RESULTS
Peptides containing arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323 were found to have (16)O/(18)O ratios greater than a cut off value of 2.0 (i.e., a cut off value based on results noted when using only normal HSA as a reference). A qualitative comparison of the (16)O- and (18)O-labeled digests indicated that lysines 525 and 439 also had significant degrees of modification. The modifications that occurred at these sites were variations of fructosyl-lysine and AGEs which included 1-alkyl-2-formyl-3,4-glycoyl-pyrole and pyrraline.


CONCLUSIONS
Peptides containing arginine 218 and lysines 212, 413, 432, and 439 contained high levels of modification and are also present near the major drug binding sites on HSA. This result is clinically relevant because it suggests the glycation of HSA may alter its ability to bind various drugs and small solutes in blood.
Barnaby
Omar S
OS
Department of Chemistry, University of Nebraska, Lincoln, NE, United States.
Wa
Chunling
C
Cerny
Ronald L
RL
Clarke
William
W
Hage
David S
DS
D000595:Amino Acid Sequence; D001665:Binding Sites; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D007553:Isotope Labeling; D010103:Oxygen Isotopes; D010446:Peptide Fragments / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism; D012709:Serum Albumin / Q000737:chemistry* / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014357:Trypsin / Q000378:metabolism
D017127:Glycation End Products, Advanced; D010103:Oxygen Isotopes; D010446:Peptide Fragments; D004364:Pharmaceutical Preparations; D012709:Serum Albumin; D014357:Trypsin
Diabetologia. 1995 Sep;38(9):1076-81
8591822
Biochem J. 1989 Aug 1;261(3):871-8
2803249
Clin Chim Acta. 2007 Oct;385(1-2):48-60
17707360
Rapid Commun Mass Spectrom. 2001;15(24):2456-65
11746917
Anal Chem. 2001 Jul 1;73(13):2836-42
11467524
Anal Biochem. 2009 Oct 1;393(1):8-22
19524544
Clin Chem. 1965 Apr;11:478-87
14277286
J Biol Chem. 1986 Oct 15;261(29):13542-5
3759977
J Mass Spectrom. 2005 Jul;40(7):969-72
15768376
Nature. 1992 Jul 16;358(6383):209-15
1630489
J Biol Chem. 2005 Feb 18;280(7):5724-32
15557329
Diabetes. 2003 Jul;52(7):1825-36
12829653
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
8744570
Rapid Commun Mass Spectrom. 2000;14(14):1226-32
10918372
Proc Natl Acad Sci U S A. 1984 Jan;81(2):583-7
6582514
Nucleic Acids Res. 2003 Jul 1;31(13):3316-9
12824316
J Pharmacol Exp Ther. 2006 May;317(2):667-75
16410405
J Am Soc Mass Spectrom. 2004 Apr;15(4):437-45
15047049
Mass Spectrom Rev. 2000 Sep-Oct;19(5):279-304
11079246
J Mol Biol. 2005 Oct 14;353(1):38-52
16169013
J Biol Chem. 1984 Mar 25;259(6):3812-7
6706980
Biochim Biophys Acta. 2003 Oct 13;1623(2-3):88-97
14572906
Biopharm Drug Dispos. 1997 Dec;18(9):791-801
9429743
Mass Spectrom Rev. 2006 Sep-Oct;25(5):775-97
16625652
Rapid Commun Mass Spectrom. 2005;19(19):2849-56
16155976
Anal Chem. 2006 Dec 1;78(23):7967-77
17134129
Bioinformatics. 2006 Nov 15;22(22):2739-45
16954138
Clin Chem. 1995 Nov;41(11):1654-61
7586558
J Mass Spectrom. 1997 Jul;32(7):773-8
9241858
Biochem J. 1999 Nov 15;344 Pt 1:109-16
10548540
Anal Biochem. 2006 Feb 15;349(2):229-41
16356458
Eur J Clin Pharmacol. 1993;45(6):577-9
8157046
J Agric Food Chem. 2003 Jan 1;51(1):51-7
12502384
Curr Med Chem. 2004 Aug;11(16):2185-93
15279557
Electrophoresis. 1997 Mar-Apr;18(3-4):403-8
9150918
J Chromatogr B Biomed Sci Appl. 2001 Aug 5;759(1):1-15
11499613
J Proteome Res. 2008 May;7(5):2025-32
18396901
Proteins. 2005 Dec 1;61(4):704-21
16231289
Biochem J. 2002 May 15;364(Pt 1):1-14
11988070